- Activity and safety of crizotinib in patients with alveolar soft part…
Number of the records: 1  

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE"

  1. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2017, 2017, roč. 12, č. 6, s. 453.
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.

Accept allSettingsReject all